Over 90% of granulosa cell tumors have a FOXL2 mutation that contributes to aromatase upregulation.
Chemotherapy has demonstrated limited efficacy in the treatment of granulosa cell tumors.
A patient with recurrent granulosa cell tumor responded briefly to anastrazole treatment.
Retreatment with another aromatase inhibitor letrozole led to a durable response of 24 months.